From the Journals

Nirsevimab Shows 83% Efficacy Over 6 Months

A large clinical trial in Europe showed that a single dose of nirsevimab reduced infant hospitalizations for RSV-associated lower respiratory tract infections by over 80% over a six-month period.

Share

A phase 3 trial across France, Germany, and the UK evaluated the monoclonal antibody nirsevimab in 8,057 infants under 12 months, finding an 82.7% reduction in hospitalizations due to RSV-associated lower respiratory tract infections. Nirsevimab demonstrated 75.3% effectiveness against severe RSV-associated LRTI and 41.9% for all-cause LRTIs. Consistent efficacy was noted across diverse age and weight categories, with no new safety concerns reported. The study indicates nirsevimab can offer prolonged protection, aligning with well-baby visit schedules.

Original Source(s)

Nirsevimab Shows 83% Efficacy Over 6 Months

A large clinical trial in Europe showed that a single dose of nirsevimab reduced infant hospitalizations for RSV-associated lower respiratory tract infections by over 80% over a six-month period.

  • by Stanley Gajete

  • July 17, 2025

  • 3 min

Related Content

Vaccine Playbook Rewrite: Who’s In Charge?

HHS Secretary Robert F. Kennedy Jr.’s changes at the CDC are prompting states and medical societies to issue independent vaccine recommendations, challenging long-standing national immunization policy.

COVID-19 Booster in Pregnancy Linked to Higher Infant Antibodies

A COVID-19 mRNA booster given during pregnancy is associated with greater transplacental antibody transfer and sustained infant antibody levels through 6 months of age.

Rotavirus Co-Inventor Removed From FDA Vaccine Committee

Paul Offit, a longtime FDA advisor and prominent figure in vaccine development, sidelined from vaccine committee amid healthcare turmoil in the US.